HOLD with tightened risk parameters — no adding until 87.50 close with RSI above 40, reduce position size to 40-50% of normal allocation until 200 SMA reclaimed on closing basis, trim to 25% sizing if 10-year breaks above 5% or 87.00 fails closing before earnings

• Stock has made six straight lower highs and four straight lower lows, currently trading below 200 SMA which is broken support, not support
• Defined drawdown path of approximately 20%: 87.00 level → 81.79 Bollinger lower band → 76 zone → 69.64 January capitulation low
• Q3 2025 printed a 3.13 dollar loss with 5.24 billion dollar charge; forward EPS of 8.53 may be optimistic given medical cost trend volatility
• 10-year at multi-decade highs with 96% Polymarket probability of no Fed cuts in 2026 creates structural cost pressure on 76 billion of debt
• Management paid down 1.77 billion last quarter but refinancing costs ratchet higher as rates rise; 14x forward PE compresses to 11x or 10x if 10-year hits 5%
• PEG of 0.20 only valid if forward earnings are credible; sector has documented reserve volatility that could reprice estimates
• Aggressive case requires five independent positive outcomes; downside requires only one negative outcome — not asymmetry but adverse skew
• Current 50-75% of defensive healthcare allocation equals 10-15 million on a 100 million book — too large for a leveraged, rate-sensitive, regulatory-exposed name below all major moving averages

→ vs aggressive: 200 SMA in a confirmed downtrend is not support, it's a level that has been broken — the coiled spring metaphor is not analysis

→ vs aggressive: PEG of 0.20 is only a buy signal if the E in PEG is credible; Q3 2025 loss of 3.13 with 5.24 billion charge and documented reserve volatility suggests forward EPS of 8.53 may be fantasy

→ vs aggressive: 38% upside math collapses into single digits as 14x PE compresses to 11x or 10x if 10-year pushes to 5%

→ vs aggressive: Balance sheet is lagging data; trailing deleveraging from past quarters does not protect against forward macro headwinds

→ vs aggressive: AEP enrollment results, Medicare Advantage Star Ratings, PBM regulatory action, and forward medical cost trend are the real forward-looking inputs and remain unpriced

→ vs aggressive: No adding until daily close above 87.50 with rising volume and RSI above 40 is a hard line, not a soft suggestion — 'if adding on confirmed setup' language is insufficient

→ vs aggressive: Wait for confirmation is not timidity, it is risk management — asymmetric trade requires five things to go right, downside requires only one

HOLD at 50% of normal defensive healthcare allocation; add to 60-65% on confirmed technical trigger ($87.50 close, 13M+ volume, RSI above 40); staged scale-out below $85 and $81.79; hard stop at $79.50; macro review trigger at 4.75% 10-year weekly close; pre-committed re-evaluation for EPS $7.50, 10-year 5%, MLR +150bps surprise

• PEG of 0.20 and $5.65B quarterly FCF represent genuine asymmetric value setup
• Forward EPS $8.53 at 14x multiple ($119) requires multiple expansion AND earnings delivery—two independent bets
• Fair multiple in 5%+ rate environment is 10-12x, not historical 12-15x; yields $85-$110 at $8.53 EPS or $84 at $7.00 EPS at 12x
• MACD histogram at +0.04 is noise, not momentum confirmation
• Q3 2025 had $5.24B unusual charge (capital impairment, business sale loss)—not clean MLR-driven event
• Capitulation to $69 requires technical breakdown below 200 SMA AND rate escalation AND MLR/Star disappointment AND no defensive bid—multiple conditions needed for bear case too
• Polymarket pricing 96% probability of no rate cuts in 2026 extends hostile macro environment into CVS earnings window
• Reactive 5% 10-year stop is too late—CVS trades with 10-year move, not after; position-sizing review should trigger at 4.75% weekly close
• Conservative analyst's 25% trim stop at $79.50 exits before historically established bounce zone
• Q3 earnings, AEP enrollment, Q4 earnings, MA Star Ratings are checkpoints, not action triggers; 6-9 month thesis horizon

→ vs aggressive: Coiled spring metaphor is rhetorical, not analytical; MACD histogram at +0.04 is barely above zero—noise, not momentum confirmation

→ vs aggressive: Forward EPS $8.53 with 14x multiple assumes historical range; in 5%+ rate world fair multiple is 10-12x, collapsing upside math to $85-$110

→ vs aggressive: Asymmetric trade requires both multiple expansion AND earnings delivery—two independent bets, not one

→ vs aggressive: Q3 earnings not 'price-discovered'; MLR print, Star Ratings commentary, utilization guidance are real informational events

→ vs conservative: Q3 2025 comparison flawed—$5.24B unusual charge (capital impairment, business sale loss) is not clean MLR-driven earnings event

→ vs conservative: Bear case requiring one catalyst vs bull case requiring five is rhetorically powerful but analytically dishonest; capitulation to $69 requires four simultaneous conditions

→ vs conservative: Reactive 5% 10-year stop is too late—position-sizing review should trigger at 4.75% weekly close to separate signal from response

→ vs conservative: Hard stop at $79.50 exits before historically established bounce zone for CVS at 200 SMA configurations